Search results for "Gonad"

showing 10 items of 240 documents

Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major

2002

We studied bone mass and metabolism in 30 adult women (age 28.5 +/- 1.3) with thalassemia major (TM) and evaluated whether prolonged hormone replacement therapy (HRT) was able to optimize bone accrual. TM patients had reduced bone mass, increased bone turnover and lower serum gonadotropin and estradiol levels compared with 10 normal women of similar age. A significant correlation was found between bone mass and sex hormone levels. Six TM patients with normal ovarian function had normal bone turnover markers and modestly low bone mass (lumbar spine -1.29 +/- 0.31; femoral neck -0.60+/-0.21; Z-score). The other 24 TM women were hypogonadic and had significantly lower bone mass for age (lumbar…

Adultmedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and MetabolismThalassemiaOsteoporosisBone remodelingAdult womenEndocrinologySex hormone-binding globulinBone DensityInternal medicinemedicineHumansOrthopedics and Sports MedicineFemoral neckEstradiolbiologybusiness.industryHypogonadismbeta-ThalassemiaOsteoporosiLuteinizing Hormonemedicine.diseaseThalassaemiaEndocrinologymedicine.anatomical_structureTransgender hormone therapyOrthopedic surgerybiology.proteinFemaleFollicle Stimulating HormonebusinessCalcified Tissue International
researchProduct

Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pill pretreatment.

2007

Objective To evaluate and compare the risk of early pregnancy loss in patients stimulated with GnRH antagonist protocols according to oral contraceptive pill (OCP) pretreatment. Design Retrospective case–control study. Setting Instituto Valenciano de Infertilidad. University of Valencia. Spain. Patient(s) One thousand five hundred thirty-nine patients, aged Intervention(s) Reproductive outcome was compared based on the application (or not) of OCP pretreatment: 944 women were included in the OCP group and 595 in the non-OCP group. The Student's t test was used for statistics. Main Outcome Measure(s) Pregnancy, biochemical pregnancy, ectopic pregnancy, early clinical pregnancy loss, early pre…

Adultmedicine.medical_specialtyOral contraceptive pillPregnancy Ratemedicine.drug_classEarly Pregnancy LossGonadotropin-releasing hormone antagonistMiscarriageGonadotropin-Releasing HormonePregnancymedicineHumansRetrospective StudiesGynecologyPregnancyEctopic pregnancybusiness.industryObstetrics and Gynecologymedicine.diseasePregnancy rateReproductive MedicinePillCase-Control StudiesEmbryo LossFemalebusinessContraceptives OralFertility and sterility
researchProduct

Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial

2013

Abstract Background Both oral contraceptive pills (OCPs) and estradiol (E2) valerate have been used to schedule gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between GnRH antagonist IVF cycles scheduled with OCPs or E2 valerate. Methods Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women 18–38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts)…

Adultmedicine.medical_specialtyPregnancy Ratemedia_common.quotation_subjectPopulationPhysiologyFertilization in VitroCycle schedulingReproductive technologyGonadotropin-releasing hormoneValerateContraceptives Oral Hormonallaw.inventionGonadotropin-Releasing HormoneEndocrinologyRandomized controlled trialPregnancylawInternal medicineGnRH antagonistHumansMedicineeducationMenstrual CycleMenstrual cyclemedia_commonchemistry.chemical_classificationeducation.field_of_studyEstradiolOral contraceptivesbusiness.industryResearchEstradiol valerateEstrogen pretreatmentObstetrics and GynecologyPregnancy rateEndocrinologychemistryReproductive MedicineIVFFemalebusinessmedicine.drugDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 400…

2010

background: The influence of elevated serum progesterone levels during in vitro fertilization/intracytoplasmic sperm injection (IVF/ ICSI) cycles on pregnancy rates is a matter of continued debate among fertility clinicians. Efforts to resolve this question have been impeded by the various assays used to measure progesterone and the different, arbitrary threshold values for defining ‘high’ progesterone levels. methods: A non-interventional, retrospective, observational, single-centre cohort study evaluated the relationship between serum progesterone levels on the day of human chorionic gonadotrophin (hCG) administration and the ongoing pregnancy rate in 4032 patients undergoing IVF/ICSI cyc…

Adultmedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentFertilityStimulationFertilization in VitroGonadotropin-releasing hormoneBiologyChorionic GonadotropinIntracytoplasmic sperm injectionCohort StudiesGonadotropin-Releasing HormoneAndrologyOvulation InductionPregnancyInternal medicinemedicineHumansProgesteroneRetrospective Studiesmedia_commonPregnancyIn vitro fertilisationbusiness.industryRehabilitationObstetrics and GynecologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseConfidence intervalPregnancy rateEndocrinologyReproductive MedicineRegression AnalysisReproductive Control AgentsGestationFemaleOvulation inductionFollicle Stimulating HormoneGonadotropinbusinesshormones hormone substitutes and hormone antagonistsHormoneHuman Reproduction
researchProduct

Characteristics of urinary luteinizing hormone (LH) during the induction of LH surges of different magnitude in blood

1995

Urinary luteinizing hormone (LH) testing has been proposed as a reliable method for the prediction of ovulation but its accuracy has been challenged by some studies. To check how accurately the oscillations of urinary LH reflected the plasma changes, surges of LH of different magnitude and duration were artificially induced in plasma and the hormone was measured simultaneously in urine. Post-menopausal women (n = 16) were stimulated during 1 week with a combination of transdermal oestradiol (400 micrograms) and i.m. progesterone (25 mg on day 4, 50 mg on day 5) to obtain an LH discharge comparable with the pre-ovulatory LH peak. A short and moderate peak of LH was induced by the i.v. inject…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classmedia_common.quotation_subjectRadioimmunoassayGonadotropin-releasing hormoneUrineBuserelinSensitivity and SpecificityGonadotropin-Releasing HormoneAndrologyInternal medicinemedicineHumansOvulationProgesteronemedia_commonOvulation DetectionEstradiolChemistryEstrogen Replacement TherapyRehabilitationReproducibility of ResultsObstetrics and GynecologyLuteinizing HormoneMiddle Agedmedicine.diseaseBuserelinMenopauseEndocrinologyReproductive MedicineFemaleMenopauseGonadotropinLuteinizing hormonemedicine.drugHormoneHuman Reproduction
researchProduct

Ovarian sex cord tumor with annular tubules in a woman with premature ovarian failure.

2001

Abstract Objective: To report a case of premature ovarian failure (POF) associated with an ovarian sex cord tumor with annular tubules. Design: Case report. Setting: Reproductive endocrinology unit in a tertiary academic center. Patient(s): A 20-year-old woman with POF. Intervention(s): Biopsy of the rudimentary ovary by laparoscopy. Main Outcome Measure(s): Protocol for POF investigation and histological study of the ovarian sample. Result(s): An ovarian sex cord tumor with annular tubules was detected in the rudimentary right ovary. Conclusion(s): The rare ovarian sex cord tumor with annular tubules, which may be hormonally active, was detected in a case of POF.

Adultmedicine.medical_specialtyendocrine system diseasesBiopsyOvaryBiologyPrimary Ovarian InsufficiencyOvarian tumorBiopsymedicineHumansSex Cord-Gonadal Stromal TumorsOvarian follicleLaparoscopyGynecologyOvarian Neoplasmsmedicine.diagnostic_testHistocytochemistryOutcome measuresObstetrics and Gynecologymedicine.diseaseOvarian Sex Cord Tumor with Annular Tubulesfemale genital diseases and pregnancy complicationsPremature ovarian failuremedicine.anatomical_structureReproductive MedicineFemaleFertility and sterility
researchProduct

Unruptured tubal pregnancy: local low-dose therapy with methotrexate under transvaginal ultrasonographic guidance.

1996

Thirty patients with unruptured ectopic pregnancy (4-10 weeks' gestation) were treated locally with methotrexate (MTX) under sonographic guidance. The transvaginal puncture was performed under analgesic sedation using an automatic puncturing device. Local MTX therapy was successful in 25 patients (83.3%). Eighteen of these patients had received a single MTX instillation with a total dose of 10 mg, 7 patients had received a second instillation with 10 mg because of plateauing hCG levels after the first instillation. In 5 patients MTX therapy was unsuccessful. Surgical intervention was necessary within 4 h to 15 days after MTX treatment, due to severe tubal bleeding (n = 1) or the development…

Adultmedicine.medical_specialtymedicine.drug_classAntimetaboliteChorionic Gonadotropinchemistry.chemical_compoundRoute of administrationPregnancyUnruptured tubal pregnancymedicineHumansUltrasonographyEctopic pregnancybusiness.industryLow doseObstetrics and Gynecologymedicine.diseaseSurgeryTrophoblastsMethotrexateReproductive MedicinechemistryAntifolateGestationMethotrexateFemalePregnancy Tubalbusinessmedicine.drugGynecologic and obstetric investigation
researchProduct

Influence of the ovary on parameters of LH secretion during the recovery from buserelin-induced desensitization

1994

Abstract This study examined the effect of the ovary on LH pulsatility and on the secretory performance of gonadotrophes during the phase of recovery after treatment with buserelin, a GnRH analogue. We included 12 patients, who received buserelin (1.2 mg/day, intranasally for 3 months) as a reductive therapy for uterine leiomyomatosis prior to hysterectomy. Six patients were oophorectomized and the other 6 patients had their ovaries preserved. LH was measured in samples taken basally up to 36 days after suppression of buserelin. LH pulsatility was studied on day 9 along a 24-h cycle, and the response of the hormone to a double-stimulus GnRH test on days 0, 9, 20, and 34. The concentration o…

Adultmedicine.medical_specialtymedicine.drug_classOvariectomymedicine.medical_treatmentRadioimmunoassayUterusEndogenyHysterectomyBuserelinLeiomyomatosisInternal medicinemedicineHumansAdministration IntranasalHysterectomybusiness.industryOvaryRemission InductionObstetrics and GynecologyOophorectomyLuteinizing HormoneMiddle AgedBuserelinEndocrinologymedicine.anatomical_structurePremenopauseReproductive MedicineIn uteroUterine NeoplasmsFemaleGonadotropinbusinessmedicine.drugHormoneEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct

Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilizat…

2007

To verify whether the antral follicle count (AFC) could predict ovarian response, oocyte/embryo quality, and IVF outcome.Prospective study.Instituto Universitario-Instituto Valenciano de Infertilidad, Valencia, Spain.One thousand seventy-four donors and 975 oocyte recipient cycles.Controlled ovarian hyperstimulation (COH), endometrial preparation, IVF/intracytoplasmic sperm injection, ET.COH and oocyte/embryo quality parameters and IVF outcome.We observed lower E(2) levels and fewer mature retrieved oocyte numbers among donors who showed an AFC that was10. These donors also showed significantly higher cancellation and no-donation rates; poor and/or insufficient response was the principal ca…

Adultmedicine.medical_specialtymedicine.medical_treatmentEmbryonic DevelopmentOocyte RetrievalCell CountFertilization in VitroControlled ovarian hyperstimulationIntracytoplasmic sperm injectionAndrologyYoung AdultEgg donationOvarian FollicleEmbryo cryopreservationPredictive Value of TestsPregnancymedicineHumansUltrasonographyGynecologyIn vitro fertilisationOocyte Donationbusiness.industryPatient SelectionOvaryPregnancy OutcomeObstetrics and GynecologyFertility Agents FemaleEmbryo MammalianAntral follicleEmbryo transferReproductive MedicineSpainFertilizationVaginaembryonic structuresOocytesFemaleLeuprolidebusinessGonadotropinsEmbryo qualityFertility and Sterility
researchProduct

Associations of Sex Hormones and Hormonal Status With Arterial Stiffness in a Female Sample From Reproductive Years to Menopause

2021

Objective: Loss of sex hormones has been suggested to underlie menopause-associated increment in cardiovascular risk. We investigated associations of sex hormones with arterial stiffness in 19–58-years-old women. We also studied associations of specific hormonal stages, including natural menstrual cycle, cycle with combined oral contraceptives (COC) and menopausal status with or without hormone therapy (HT), with arterial stiffness. Methods: This study includes repeated measurements of 65 healthy women representing reproductive (n=16 natural, n=10 COC-users) and menopause (n=5 perimenopausal, n=26 postmenopausal, n=8 HT-users) stages. Arterial stiffness outcomes were aortic pulse wave veloc…

AdultnaisetAdolescentvaihdevuodetBlood PressurekuukautisetPulse Wave Analysisreproductive hormoneshormonaaliset tekijätYoung AdultEndocrinologyVascular StiffnessHeart Ratewomen’s healthHumanspulse wave analysisArterial PressureGonadal Steroid HormonesMenstrual CycleOriginal ResearchsukupuolihormonitEstradiolhormonal contraceptionvascular stiffnessMiddle Agedhormone replacement therapyikääntyminenkuukautiskiertoFollicular Phasevascular aginghormonihoitosydän- ja verisuonitauditFemaleFollicle Stimulating HormoneMenopausemenstruation
researchProduct